Areas of Focus:

Biological & MechanisticBiomarker DiscoveryClinical TrialsData-Driven & QuantitativeDisease SubtypingExperimental Platforms & ModelsHuman CohortsMicrobiome–Immune InteractionsMulti-omics IntegrationTranslational & ClinicalCross-Cutting & Special PopulationsRare Autoimmune DiseasesSystemic DiseasesVasculitis
  • Assistant Professor, Department of Medicine, Perelman School of Medicine, University of Pennsylvania

Dr. Rennie Rhee is Assistant Professor of Medicine in the Division of Rheumatology at the Perelman School of Medicine and a member of the Penn Vasculitis Center. She received her MD from the New York University School of Medicine in 2008, completed internal medicine residency at NYU, rheumatology fellowship at Penn from 2011 to 2013, and earned her MSCE at the University of Pennsylvania.

Dr. Rhee’s research integrates high-dimensional molecular, imaging, and clinical data to understand and predict outcomes in ANCA-associated vasculitis and giant cell arteritis. She founded the Penn Giant Cell Arteritis Fast-Track Program to accelerate diagnosis and treatment of GCA and led the development of an NIH-funded longitudinal biorepository of more than 900 nasal swab specimens from patients with vasculitis to study upper airway mucosal immunity in relapse.

Dr. Rhee is a Penn Colton Center Cohort pilot awardee, integrating multi-omic assessment of the upper airway mucosa with deep immune profiling of blood to understand the molecular drivers of vasculitis relapse. She contributes to national and international vasculitis guidelines and is a senior collaborator within the VCRC, the Institute for Immunology and Immune Health, and the Penn Colton Center.

Projects

Featured Pilot Projects

Molecular Determinants of Systemic Immune Reactivation in Patients with ANCA-Associated Vasculitis
Project | University of Pennsylvania

Molecular Determinants of Systemic Immune Reactivation in Patients with ANCA-Associated Vasculitis

Profiling deep immune changes before AAV relapse to identify predictive biomarkers and therapeutic targets for this difficult-to-manage autoimmune vasculitis.